The hidden data gap behind parasitic disease control
Who is this article for? Healthcare authorities, Ministries of Health

The hidden data gap behind parasitic disease control

DIDIDI team

For health authorities, closing the gap means connecting diagnostic capacity, representative surveillance and population care—not simply collecting more records.

A district reports fewer parasitic infections than last year. This may reflect successful control. It may also reflect fewer tests, incomplete reporting or reduced access to care. Before using the decline to reduce resources, a health authority needs to establish which explanation the evidence supports.

WHO’s 2025 schistosomiasis guidance specifically addresses the interpretation of routine health-facility data, including diagnosis, treatment, geographical patterns and data quality. Its relevance extends beyond reporting: authorities need information that distinguishes changes in disease from changes in the system observing it. 1

The stakes are substantial. WHO’s Global report on neglected tropical diseases 2025 estimated that 1.495 billion people required NTD interventions in 2023 and highlighted continuing problems with complete reporting and gender-disaggregated data. NTDs include conditions caused by several types of pathogens, not only parasites; the figure is therefore a measure of the wider NTD challenge rather than a count of parasitic infections. 2

This article focuses particularly on schistosomiasis and soil-transmitted helminth infections, with implications for national and subnational policy. Its central recommendation is to treat data quality as part of service delivery: fund the ability to detect infections, identify underserved populations and act on findings together.

1. Separate the questions that different data can answer

WHO’s 2025 general NTD information-system guidance distinguishes population surveys, routine health-facility reporting and reports from community interventions. It recommends integrating NTD data within established national information pathways, with validation, analysis and use at successive levels. These sources should inform one another without being treated as interchangeable. 3

Routine consultation records describe people who reach participating services and are recognised and recorded. A representative prevalence survey estimates infection in its defined sampling population. A treatment register measures delivery to people targeted by an intervention. None automatically measures the others.

For authorities, the first practical reform is to require a short interpretation statement with every major indicator: who is included, what was measured, how the denominator was obtained and which decision the indicator supports. WHO’s indicator compendium provides standard definitions and metadata intended to improve comparability over time and between programmes. 4

This distinction matters for care. A district can deliver a successful treatment campaign while retaining gaps in diagnosis and management of symptomatic patients. Conversely, improved clinical detection may raise reported case numbers even as access improves. These are reasons to interpret indicators jointly, not reasons to distrust surveillance.

2. Make diagnostic capacity visible in disease reports

The laboratory method changes what a surveillance system can see. A 2014 meta-analysis estimated double-slide Kato–Katz sensitivity at 74–95% across the soil-transmitted helminth groups studied in high-intensity infections, falling to 53–80% in low-intensity settings. These historical pooled estimates are not fixed correction factors for current national datasets. They demonstrate why apparent prevalence depends partly on diagnostic performance. 5

The problem becomes especially important as programmes succeed. WHO’s schistosomiasis diagnostic target product profiles recognise that traditional egg-detection methods lack sensitivity in low-intensity infections, precisely the situations encountered when investigating interruption of transmission. 6

Authorities should therefore retain the diagnostic method, specimen strategy, survey date and quality-assurance information alongside prevalence estimates. When a method changes, a comparability assessment should precede interpretation of the resulting trend. A rise following introduction of a more sensitive test cannot automatically be attributed to rising transmission.

Routine reporting should also make testing activity visible. As an illustration—not observed programme data—100 positive results among 1,000 tests represents 10% positivity; 100 among 2,000 represents 5%. Neither is population prevalence unless the sampling design supports that interpretation.

Record people tested and tests performed separately where repeat testing is common. This proposed practice helps prevent changes in diagnostic workload from being mistaken for changes in the number of people investigated.

3. Audit treatment coverage, including its denominator

Treatment coverage is a public-health measure with a specific meaning. WHO defines preventive-chemotherapy coverage in relation to people needing treatment who actually swallowed the medicines. Its field manual identifies incorrect tallying, population shifts, outdated census information and treatment outside the targeted group as sources of bias. 7

Current global figures illustrate why interpretation matters. For schistosomiasis in 2024, WHO reported preventive-treatment coverage of 61.7% among school-aged children and 14.6% among adults at risk. These are coverage estimates for populations requiring preventive chemotherapy, not infection prevalence or clinical cure rates. 8

For soil-transmitted helminthiases, WHO reported that more than 883 million children required preventive chemotherapy in 2024, with approximately 506.6 million treated and global coverage of 57.4%. These programme estimates should not be read as counts of laboratory-confirmed infections. 9

Health authorities should publish numerator and denominator definitions with coverage estimates, document population revisions and distinguish programme targets from total eligible populations. WHO’s STH databank explicitly differentiates geographical, programme and national coverage. A percentage based on a selected operational target can answer a different question from coverage of everyone requiring treatment. 10

Use WHO’s coverage evaluation surveys and data-quality assessments to investigate doubtful results. Medicine stocks and distribution records can support reconciliation, but tablets dispatched are not equivalent to verified ingestion. The purpose of an audit should be to identify missed people and correct delivery, not merely validate a headline percentage. 7

4. Match geographical detail to the decision

Schistosomiasis transmission is focal. District-wide averages can consequently be too coarse for some intervention decisions. WHO/ESPEN’s Practical and Precision Assessment approach explicitly addresses whether implementation should remain at district level or move towards subdistrict targeting. Its guidance also stresses feasibility, local epidemiology and the technical capacity needed for planning and interpretation. 11

The policy response is not to demand exhaustive high-resolution mapping everywhere. Authorities should first identify the decision that additional detail would change: treatment frequency, intervention geography or investigation of a possible persistent focus.

Use historical surveys, treatment records and environmental information to prioritise assessment, then apply an appropriate survey design. Deliberately selected high-risk sites may identify a focus, but they should not be presented as a representative prevalence estimate for the entire district.

For each map, retain the survey year, diagnostic method, population sampled, administrative boundaries and uncertainty. A map without this context can conceal differences between a recent impact assessment and an old baseline.

ESPEN’s geospatial tool provides an example of decision support built around existing data and a defined assessment protocol. Its published description identifies prototype and pilot functions; it should not be treated as evidence that automated mapping has already resolved targeting uncertainty in every setting. 11

5. Ask whose infections and care needs remain poorly represented

The disparity between reported schistosomiasis treatment coverage in adults and school-aged children should prompt age-specific review. It does not, by itself, establish which delivery model caused the gap or quantify adult disease burden. It does establish that a single combined coverage figure would conceal an important difference. 8

Different conditions can also be invisible to the same diagnostic platform. WHO’s 2024 strongyloidiasis guideline addresses a distinct public-health strategy for Strongyloides stercoralis. An authority should not assume that a dataset generated for the usual soil-transmitted helminths adequately characterises strongyloidiasis or determines its control needs. 12

Morbidity may require evidence beyond egg detection. WHO notes the diagnostic difficulties of genital schistosomiasis and the need for systematic differential assessment because manifestations can resemble other infections and premalignant or malignant conditions. Routine parasite-positive counts alone cannot describe the full need for these clinical services. 13

Authorities should select useful disaggregation—such as age, sex and location—and assess whether delivery and sampling approaches omit relevant groups. Where justified locally, this may include children outside school, mobile populations and occupationally exposed communities. These are proposed priorities for an equity review, not a claim that every national dataset omits the same groups.

Additional information should lead to a response: outreach, accessible diagnosis, referral, treatment or morbidity management. Documenting disadvantage without budgeting for care leaves the policy objective incomplete.

6. Establish a minimum dataset with an explicit response

WHO’s routine schistosomiasis guidance supports monitoring diagnosis and treatment and examining the limits and quality of facility data. Authorities can use it as the disease-specific foundation, adapting reporting to national clinical and programme definitions. 1

The following is a proposed decision framework, rather than a new WHO indicator standard. It separates signals that often need different actions.

Data component Interpretation requirement Potential policy response
Suspected cases, people tested and confirmed cases Consistent definitions; test method and repeat testing understood Review diagnostic access and investigate unusual patterns
Treatment after clinical diagnosis Link treatment to the relevant episode and eligibility Address medicine shortages, referral failures or access barriers
Preventive-treatment coverage Defined eligible population; medicines swallowed rather than merely supplied Validate low or implausible coverage and organise corrective delivery
Facility reporting and test availability Distinguish missing reports, unavailable testing and reported zero cases Restore service capacity or follow up reporting gaps
Survey results Sampling population, date, method and uncertainty retained Review programme impact and intervention geography
Morbidity and referral needs Agreed clinical categories and patient follow-up arrangements Plan appropriate clinical and disability-related care

Missing information should be visibly coded. “No report,” “no testing available” and “no cases detected after testing” are different operational situations. Treating all three as zero would erase the distinction the system needs to preserve.

Keep the dataset proportionate. Every additional field should have a defined use, an accountable reviewer and a realistic collection process. WHO’s 2025 guidance favours minimum disease-specific indicators within established national pathways rather than duplicated, fragmented reporting. 3

7. Improve data quality before adding more dashboards

WHO’s data-quality desk-review framework examines completeness, internal consistency, external comparisons and the consistency of population data. These are practical checks for a parasitic-disease programme before interpreting an apparent hotspot or a sudden decline. 14

A feasible national approach is to combine routine automated checks with targeted verification. Review missing reports, unexplained discontinuities, unusually high coverage and disagreements between related indicators. Check the underlying records where a finding could materially change intervention policy.

WHO’s site-assessment guidance provides tools for data verification and system assessment, including checklists usable by facility staff and district supervisors. This offers a route for investigating whether an inconsistency began in clinical recording, aggregation or transmission of reports. 15

Digital integration should support that process. WHO’s Integrated Data Platform is powered by DHIS2, while the wider RHIS toolkit provides analysis and data-quality resources. Countries do not necessarily need a new disease-specific application to begin improving data use. 16 17

The recommendation is to agree identifiers, definitions, reporting responsibilities and correction procedures before commissioning additional interfaces. Maintain a functioning route for facilities with unreliable connectivity, and budget for supervision and staff time. Software procurement should include the recurring support needed to operate the service; a dashboard alone cannot establish the validity of its inputs.

When indicators disagree, investigate before reallocating

The following examples illustrate how authorities could respond to conflicting signals. They are hypothetical decision situations, not findings from a named national programme.

Reported clinical cases fall while testing also falls. Review diagnostic availability, staffing and reporting before interpreting the decline as control success. If service disruption is documented, restoring access may be the immediate response. The programme should then establish a comparable observation period before making a claim about disease trends.

Campaign coverage is high, but a survey identifies continuing infection. First check whether the campaign and survey refer to the same population, place and period. Examine coverage quality, diagnostic methods and the programme’s disease-specific expectations. Continuing infection alone does not establish medicine failure, poor adherence or renewed transmission as the explanation. Each requires appropriate investigation.

A community signal is positive while facility notifications remain low. Verify the signal and assess the clinical and sampling pathways. A targeted investigation may be justified; immediate extrapolation to district-wide prevalence is not. The action should be proportionate to the quality of the evidence and the consequences of delay.

These examples apply the comparability and verification principles in WHO’s indicator and data-quality resources. 4 14 15 A national review template could require teams to state the competing explanations, the evidence needed to distinguish them, an accountable investigator and the interim care response. This helps make uncertainty manageable without pretending that every inconsistency can be settled through a dashboard. It also allows new evidence to change an earlier decision transparently.

8. Add environmental and climate information for defined purposes

Environmental surveillance may help authorities identify transmission risks beyond the patients attending clinics. A study published online in December 2025 evaluated Schistosoma mansoni environmental-DNA detection in water from Lakes Albert and Victoria in Uganda. It compared sampling and laboratory approaches and reported differences in DNA recovery between methods. This provides evidence for technical optimisation, not proof that a water result directly measures human prevalence. 18

A defensible policy approach is to use such signals to prioritise investigation, then link them with appropriate human, snail or other epidemiological evidence. A positive environmental result is not an individual diagnosis. A negative sample should not be treated as proof that a site is permanently free of transmission.

Before scaling, specify sampling locations, frequency, analytical controls and the action a result would trigger. Evaluate whether the information improves decisions enough to justify its recurring costs.

Climate data also require care. A WHO-supported 2024 scoping review found important gaps and geographical imbalance in research on climate change, malaria and NTDs, including substantial attention to lower-burden countries with better healthcare access. 19

Authorities should treat climate-linked forecasts as decision-support hypotheses requiring local evaluation. Correlation between rainfall and reported cases can be influenced by service access, testing and reporting as well as transmission. Pilot whether a forecast improves an operational decision—such as the timing of investigation—before using it to redirect substantial resources.

9. Protect communities while increasing data visibility

More precise data create responsibilities. WHO’s 2025 ethics framework for wastewater and environmental surveillance addresses privacy, stigma, community engagement, transparency and equitable distribution of benefits and burdens. Population-level samples do not remove the need to consider how a community might be affected by the interpretation or release of findings. 20

Authorities should define who can access detailed location and patient information, what is released publicly and how potentially stigmatising interpretations are prevented. Explain surveillance aims and communicate findings with uncertainty and the planned response.

WHO’s wider ethical guidance also addresses the balance between public benefit, privacy, autonomy and equity in surveillance. Data sharing should therefore have a clear purpose and governance arrangement, particularly when moving between clinical services, research projects and commercial systems. 21

For parasitic-disease programmes, a practical principle is to connect detection with benefit. Communities asked to contribute specimens or participate in surveys should have clear information about results, access to appropriate care and the intended public-health action. Improving a map should not take precedence over managing the needs identified through its creation.

10. Finance surveillance as part of care and sustained control

The World Health Assembly’s 2023 resolution on strengthening diagnostics capacity places diagnostics within a comprehensive health-system approach. This supports a budgetary argument: information investment must include the capacity to generate reliable findings and respond clinically, not only the systems receiving reports. 22

Cost proposals should therefore cover diagnostic supplies, quality assurance, specimen referral, survey teams, data staff, supervision and the clinical response to detected disease. Authorities should compare the cost of alternative ways to answer the same decision question, rather than default to the largest dataset or most sophisticated platform.

WHO’s NTD monitoring and evaluation framework treats monitoring as an integral component of interventions and promotes standardised indicators for accountability. A proposed national implementation step is to attach an owner, review schedule and corrective-action budget to the selected indicators. 23

Maintaining surveillance also matters after progress is recognised. WHO distinguishes elimination of schistosomiasis as a public-health problem from interruption of transmission. Its Elimination Review Group’s remit includes recommendations on post-validation surveillance, sustainability and prevention of reintroduction. A successful milestone should therefore lead to an appropriate surveillance transition, rather than automatic withdrawal of observation and care. 24

A feasible first-year policy agenda

The following sequence is a proposed implementation approach drawn from the frameworks above, not an independently evaluated package.

First quarter: establish what is known. Map data sources and diagnostic capacity. Review indicator definitions, denominator quality, reporting completeness and major gaps in population coverage. Identify a small number of decisions that better information would change.

Second quarter: strengthen a limited implementation area. Pilot the minimum dataset in selected districts. Link laboratories, facilities and programme teams; provide training and a route for correcting records. Verify that detected cases can receive care.

Third quarter: validate and investigate. Conduct targeted data-quality assessments or coverage surveys where uncertainty is consequential. Review method comparability and prioritise appropriate geographical assessments.

Fourth quarter: assess value and scale selectively. Examine whether findings led to completed actions: restored testing, additional treatment access, resolved referrals or revised intervention planning. Expand processes that proved usable and affordable, with explicit recurrent funding.

This approach does not require waiting for complete national data. It requires making uncertainty visible, prioritising the most consequential gaps and documenting the response.

Where DIDIDI can contribute

DIDIDI’s published programme connects individual digital diagnostics, community-level sampling and integration of diagnostic and climate information into health-information systems. Planned work in Uganda and Kenya includes field evaluation, health-economic assessment and policy translation. These are development and research objectives, not established evidence of improved national surveillance performance. 25

For health authorities, the relevant opportunity is to help shape evaluation around practical questions: does the technology detect infections reliably in the intended setting, reveal information missed by existing approaches and support an affordable response? Community and environmental signals will need validation against appropriate reference evidence and a clear account of what they can infer about human infection. 25

The hidden data gap will close when better detection, representative measurement and accessible care reinforce one another. The policy objective is evidence that helps authorities reach people whose needs would otherwise remain unseen.

References

Sources checked on 2 November 2026. Statistical years are specified in the article. NTD figures are distinguished from parasite-specific indicators; coverage is distinguished from prevalence. The proposed dataset, operational examples and first-year agenda are policy recommendations derived from the sources, not claimed WHO standards or proven intervention packages.

  1. WHO (2025). Routine health information system and health facility data for neglected tropical diseases: Schistosomiasis. 31 August 2025. www.who.int/publications/i/item/9789240107540

  2. WHO (2025). Global report on neglected tropical diseases 2025. Epidemiological and programme data principally for 2023, with selected 2024 information. www.who.int/teams/control-of-neglected-tropical-diseases/global-report-on-neglected-tropical-diseases-2025

  3. WHO (2025). Routine health information system and health facility data for neglected tropical diseases: general guidance for national programme managers and data clerks. www.who.int/publications/i/item/9789240107076

  4. WHO (2023). A compendium of indicators for monitoring and evaluating progress of the road map for neglected tropical diseases 2021–2030. www.who.int/publications/i/item/9789240062863

  5. Nikolay B, Brooker SJ, Pullan RL (2014). Sensitivity of diagnostic tests for human soil-transmitted helminth infections: a meta-analysis in the absence of a true gold standard. International Journal for Parasitology, 44, 765–774. pubmed.ncbi.nlm.nih.gov/24992655/

  6. WHO (2021). Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes. www.who.int/publications/i/item/9789240031104

  7. WHO (2019). Preventive chemotherapy: tools for improving the quality of reported data and information: a field manual for implementation. www.who.int/publications/i/item/9789241516464

  8. WHO Global Health Observatory. Schistosomiasis (Bilharzia). Treatment data for 2024. www.who.int/data/gho/data/themes/topics/topic-details/GHO/ntd-schistosomiasis

  9. WHO Global Health Observatory. Soil-transmitted helminthiases. Treatment data for 2024. www.who.int/data/gho/data/themes/topics/soil-transmitted-helminthiases

  10. WHO. PCT Databank—Soil-transmitted helminthiases. Definitions of geographical, programme and national coverage. www.who.int/teams/control-of-neglected-tropical-diseases/data-platforms/pct-databank/soil-transmitted-helminthiases

  11. WHO/ESPEN. Schistosomiasis Mapper Tool and Practical and Precision Assessment Protocol. Includes tool status and protocol context as described from April 2024. espen.afro.who.int/tools-resources/advanced-analytical-tools/schistosomiasis-mapper-tool

  12. WHO (2024). WHO guideline on preventive chemotherapy for public health control of strongyloidiasis. www.who.int/publications/b/73256

  13. WHO (2020). Schistosomiasis: Genital manifestations. www.who.int/news-room/questions-and-answers/item/schistosomiasis-genital-manifestations

  14. WHO (2023). Data quality assurance: module 2—discrete desk review of data quality. www.who.int/publications/i/item/9789240047389

  15. WHO (2023). Data quality assurance: module 3—site assessment of data quality: data verification and system assessment. www.who.int/publications/i/item/9789240049123

  16. WHO. Control of Neglected Tropical Diseases: Data platforms and tools. Includes WHO Integrated Data Platform information. www.who.int/teams/control-of-neglected-tropical-diseases/data-platforms-and-tools

  17. WHO. Toolkit for Routine Health Information Systems Data: Modules. www.who.int/data/data-collection-tools/health-service-data/toolkit-for-routine-health-information-system-data/modules

  18. Wambui CW et al. (2025/2026). Advancing schistosomiasis monitoring through optimised environmental DNA detection. Food and Waterborne Parasitology, 42, e00313. Published online 20 December 2025; March 2026 collection. pubmed.ncbi.nlm.nih.gov/41541812/

  19. WHO (2024). New research flags the urgent need for research and evidence on the impact of climate change on neglected tropical diseases and malaria. Summary of the WHO-supported scoping review, 22 May 2024. www.who.int/news/item/22-05-2024-new-research-flags-the-urgent-need-for-research-and-evidence-on-the-impact-of-climate-change-on-neglected-tropical-diseases-and-malaria

  20. WHO (2025). Ethics framework for wastewater and environmental surveillance. pandemichub.who.int/publications/9789240116412

  21. WHO (2017). WHO guidelines on ethical issues in public health surveillance. www.who.int/publications-detail-redirect/who-guidelines-on-ethical-issues-in-public-health-surveillance

  22. World Health Assembly (2023). WHA76.5: Strengthening diagnostics capacity. apps.who.int/gb/ebwha/pdf_files/WHA76/A76_R5-en.pdf

  23. WHO (2021). Ending the neglect to attain the Sustainable Development Goals: a framework for monitoring and evaluating progress of the road map for neglected tropical diseases 2021–2030. www.who.int/publications/i/item/9789240023680

  24. WHO (2026). Schistosomiasis Elimination Review Group. Elimination distinctions and post-acknowledgement surveillance responsibilities. www.who.int/news-room/articles-detail/schistosomiasis-elimination-review-group

  25. DIDIDI. Project description. Published work-package and evaluation plans. www.dididi.eu/project/project-description